Dupixent Market Report 2025 The Business Research Company's Global Dupixent Market Outlook 2025-2034: Growth Drivers, Share, And Trends ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing ...

Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

Sanofi (OTCMKTS:SNYNF – Get Free Report) was the target of a large decline in short interest in February. As of February 28th ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...

Sanofi (EPA:SAN – Get Free Report) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of €99.23 ($107.86) and traded as high ...

Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, ...

Jim Cramer said in response to a question during a recent program on CNBC that he’d recommend investors own Regeneron ...